Across TCGA pan-cancer cohorts, PIWIL2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PIWIL2 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PIWIL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PIWIL2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.
BRCA, ESCA, and LUAD are the cancer types where PIWIL2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.